Patient acceptability of circulating tumour DNA testing in endometrial cancer follow-up.

ABSTRACT:

Objective

Circulating tumour DNA (ctDNA) is emerging as a potential option to detect disease recurrence in many cancer types, however, ensuring patient acceptability of changing clinical practice and the introduction of new technology is paramount.

Methods

Patients enrolled in a non-intervention cohort study determining the ability of ctDNA to detect recurrent endometrial cancer (EC) were invited to participate in a semi-structured interview. Analysis was performed by Template Analysis.

Results

Eighteen patients were interviewed. A ctDNA blood test was viewed by participants as more physically and psychologically acceptable than clinical examination to monitor for EC recurrence. In particular, participants expressed overwhelming preference for a blood test rather than

SUBMITTER: Relton A 

PROVIDER: S-EPMC11475366 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature